PIK3CA and breast carcinoma: LY294002, a specific inhibitor of the PI3K pathway, can decrease the rate of cell growth and increase the therapeutic sensitivity in MCF7 cells expressing wild-type p53, which may be useful for the treatment of breast cancer [56].